The study of Xiang et al. demonstrated that the RANKL antagonist, OPG, is inhibited by the correction of hyperglycemia [28], which may explain the elevated RANKL levels observed during the active phase of CN [27]. The gene discussed is TNFSF11; the disease is Hyperglycemia.